Management of Chronic Diastolic Heart Failure with Nephrotoxicity

Immediate Vancomycin Management

• The American College of Cardiology and the Infectious Diseases Society of America recommend discontinuing or adjusting vancomycin dosing immediately in patients with nausea and elevated BUN, indicating vancomycin-induced nephrotoxicity, with a target trough concentration of 15-20 mg/L to minimize nephrotoxicity risk 1

Diastolic Heart Failure Management

• The European Society of Cardiology recommends using loop diuretics cautiously as the primary therapy for fluid overload in diastolic heart failure with renal dysfunction, avoiding excessive diuresis that worsens prerenal azotemia, with a strength of evidence level of I 3
• The European Society of Cardiology suggests that if GFR is severely reduced, thiazide diuretics are ineffective as monotherapy but can be combined synergistically with loop diuretics for resistant fluid overload, with a strength of evidence level of IIa 4

ACE Inhibitor/ARB Considerations

• The European Society of Cardiology recommends continuing ACE inhibitors or ARBs at the lowest effective dose with intensive monitoring in patients with diastolic heart failure and renal dysfunction, as they may improve diastolic function but carry risk in acute renal dysfunction, with a strength of evidence level of I 3
• The European Society of Cardiology suggests monitoring renal function and electrolytes every 5-7 days until stable, then every 3-6 months, in patients with diastolic heart failure and renal dysfunction, with a strength of evidence level of IIa 5

Beta-Blocker Therapy

• The European Society of Cardiology recommends initiating or continuing beta-blockers to lower heart rate and increase diastolic filling period in patients with diastolic heart failure, with a strength of evidence level of I 3

Monitoring Strategy

• The European Society of Cardiology recommends implementing daily monitoring of renal function and electrolytes during the acute phase of diastolic heart failure with renal dysfunction, with a strength of evidence level of I 8

Specific Medications to Avoid

• The European Society of Cardiology recommends discontinuing NSAIDs, coxibs, and any other nephrotoxic agents immediately in patients with diastolic heart failure and renal dysfunction, as they worsen both vancomycin nephrotoxicity and cardiorenal syndrome, with a strength of evidence level of I 5

Alternative Antibiotic Selection

• The Infectious Diseases Society of America recommends consulting infectious disease to switch to a non-nephrotoxic alternative antibiotic if vancomycin is not absolutely required for the specific pathogen, with a strength of evidence level of IIa 1